CN Patent

CN102526737B — 二肽基肽酶iv抑制剂制剂

Assigned to Boehringer Ingelheim International GmbH · Expires 2015-02-25 · 11y expired

What this patent protects

本发明涉及具有氨基的DPP IV抑制剂的药物组合物，其制备及其治疗糖尿病的用途。

USPTO Abstract

本发明涉及具有氨基的DPP IV抑制剂的药物组合物，其制备及其治疗糖尿病的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN102526737B
Jurisdiction
CN
Classification
—
Expires
2015-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.